LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Exhaled Breath Test Diagnosis of Cancer Assessed

By LabMedica International staff writers
Posted on 29 May 2018
Image: The GastroCHECK Gastrolyzer breath test monitor (Photo courtesy of coVita).
Image: The GastroCHECK Gastrolyzer breath test monitor (Photo courtesy of coVita).
In the United Kingdom, upper gastrointestinal symptoms account for at least 3% of consultations in primary care and many patients present with advanced-stage disease and only 38% of cases can be treated with a curative intent.

Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms. Volatile organic compounds (VOCs) emitted from the human body have been of interest to scientists for several decades, with associations previously suggested between specific VOCs and breath and lung, bladder, and breast cancers.

In a multicenter diagnostic study, led by those at Imperial College London (UK), scientists recruited 335 patients, including 172 patients with esophagogastric cancer; a breath test demonstrated good diagnostic accuracy. Patients 18 years or older with upper gastrointestinal symptoms attending for endoscopy or surgery were eligible. In the cancer cohort only patients with histologically confirmed nonmetastatic esophagogastric adenocarcinoma (stage I-III) were included. All patients in the cancer cohort were sampled when they were neoadjuvant naive.

Patients were asked to perform a single deep nasal inhalation followed by complete exhalation via their mouth into secure 500-mL steel breath bag (GastroCHECK, coVita, Santa Barbara, CA, USA) via a 1-mL Luer-lok syringe. Patients in the cancer and control groups were recruited consecutively. Breath samples were returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Histopathology examination of tissues obtained via endoscopy or from surgically resected specimens was carried out. The reference test was considered positive on OGC histopathology diagnosis.

The scientific team reported that patients in the OGC group were older (median [IQR] age 68 [60-75] versus 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) versus women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC.

The authors concluded that their study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting as the validation study showed a sensitivity of 80% and a specificity of 81% for the breath test to diagnose esophagogastric cancer. The study was published May 17, 2018, in the journal JAMA Oncology.

Related Links:
Imperial College London
coVita

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more